USPTO Examiner WEIDNER ADAM M - Art Unit 1649

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17136189TAU-BINDING ANTIBODIESDecember 2020April 2023Allow2710NoNo
17136440TAU-BINDING ANTIBODIESDecember 2020March 2023Allow2710NoNo
17130477BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USEDecember 2020July 2023Allow3120NoNo
17128110B-CELL EPITOPE OF TRICHINELLA SPIRALIS CYSTEINE PROTEASE INHIBITOR, HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY AND USES THEREOFDecember 2020December 2022Allow2410YesNo
17126677ANTIBODY FOR SKEWING SEX RATIO AND METHODS OF USE THEREOFDecember 2020June 2023Allow3010NoNo
17125172METHODS FOR IMPROVING DRUG EFFICACYDecember 2020January 2024Abandon3720NoNo
17122325HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAMEDecember 2020April 2023Allow2810YesNo
17110969ANTI-TAU ANTIBODIES AND METHODS OF USEDecember 2020September 2022Allow2100NoNo
17109604ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAINDecember 2020April 2023Abandon2810NoNo
17059268ANTI-THYROID HORMONE (T4) RECOMBINANT ANTIBODY OR ANTIGEN BINDING FRAGMENTNovember 2020October 2022Allow2320YesNo
17056816BIOPHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODY VARIANTSNovember 2020November 2022Allow2410NoNo
17098970METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASENovember 2020March 2023Allow2810NoNo
17097592COMPOSITION CONTAINING PORIA COCOS PEEL EXTRACT FOR TREATING NEURODEGENERATIVE DISORDERSNovember 2020January 2023Abandon2610YesNo
17093541ANTIBODY BINDING A LINEAR EPITOPE OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOFNovember 2020August 2021Allow1020YesNo
17093527ANTIBODY BINDING A LINEAR EPITOPE OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOFNovember 2020August 2021Allow920NoNo
17090359Immunological Targeting of Pathological Tau ProteinsNovember 2020June 2023Allow3111NoNo
17089599ANTIBODIES RECOGNIZING TAUNovember 2020December 2023Abandon3721NoNo
17089416ANTIBODIES RECOGNIZING TAUNovember 2020October 2022Allow2310NoNo
17088307AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHYNovember 2020August 2022Allow2110NoNo
17050947ANTIBODY DIRECTED AGAINST A TAU-DERIVED NEUROTOXIC PEPTIDE AND USES THEREOFOctober 2020September 2022Abandon2210NoNo
17050056USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAINOctober 2020December 2022Allow2520NoNo
17050072SERUM ALBUMIN BINDING ANTIBODIES FOR TUNEABLE HALF-LIFE EXTENSION OF BIOLOGICSOctober 2020April 2022Allow1810YesNo
17076772TREATING REFRACTORY MIGRAINEOctober 2020March 2021Allow510NoNo
17076759TREATING REFRACTORY MIGRAINEOctober 2020March 2021Allow510NoNo
17046551ANTIBODIES AGAINST BST1 FOR PREVENTING OR TREATING MYELODYSPLASTIC SYNDROMEOctober 2020December 2022Abandon2620NoNo
17067100ANTI-TAU ANTIBODIES AND METHODS OF USEOctober 2020February 2022Allow1610NoNo
17021042ANTI-SARS-COV-2 ANTIBODIES AND APPLICATION THEREOFSeptember 2020January 2023Abandon2810NoNo
17017685SYSTEMS AND METHODS FOR THE PREPARATION OF PEPTIDE-MHC-I COMPLEXES WITH NATIVE GLYCAN MODIFICATIONSSeptember 2020December 2023Abandon3911NoNo
17004447AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHYAugust 2020January 2022Allow1700YesNo
16975120CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONIST ANTIBODIESAugust 2020October 2022Allow2610NoNo
16998291THERAPEUTIC ANTIBODIES FOR TREATMENT OF NEURODEGENERATIONAugust 2020April 2022Abandon2010NoNo
16986615Anti-PHF-Tau Antibodies and Uses ThereofAugust 2020February 2022Allow1810NoNo
16985780Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 HydrolaseAugust 2020March 2022Allow1921NoNo
16943123ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOFJuly 2020January 2023Allow3020YesNo
16965271THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERSJuly 2020July 2022Allow2420NoNo
16961737FACTOR H POTENTIATING ANTIBODIES AND USES THEREOFJuly 2020February 2022Allow2020NoNo
16926062HUMANIZED TAU ANTIBODIES IN ALZHEIMER'S DISEASEJuly 2020January 2022Allow1810NoNo
16959385MISFOLDED TDP-43 BINDING MOLECULESJune 2020May 2022Allow2310YesNo
16909398Novel Anti-Human Transferrin Receptor Antibody Capable of Penetrating Blood-Brain BarrierJune 2020March 2021Allow910YesNo
16955644PURIFIED ARYLSULFATASE A AND COMPOSITONS THEREOFJune 2020December 2023Abandon4221NoNo
16903271Humanized Antibodies That Recognize Alpha-SynucleinJune 2020January 2022Allow1910NoNo
16954483ANTI-LRP5/6 ANTIBODIES AND METHODS OF USEJune 2020February 2023Allow3211NoNo
16899307MONOCLONAL ANTIBODIES TARGETING PHF1 AND AT8 EPITOPES OF HUMAN TAU PROTEINJune 2020May 2022Allow2420YesNo
16772043ANTI-ALPHA SYNUCLEIN ANTIBODIESJune 2020December 2021Allow1810YesNo
16771993ANTI-ALPHA-SYNUCLEIN ANTIBODIESJune 2020November 2021Allow1710NoNo
16895471AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHYJune 2020August 2022Allow2610NoNo
16893678ANTI-TAU ANTIBODIES AND METHODS OF USEJune 2020March 2022Allow2210NoNo
16768091CELL CULTURE METHODSMay 2020May 2023Allow3611YesNo
16768429POLYOMAVIRUS NEUTRALIZING ANTIBODIESMay 2020April 2022Allow2210YesNo
16767152Compositions and Methods for Cancer TherapyMay 2020February 2022Allow2111NoNo
16883515STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATIONMay 2020March 2022Allow2210YesNo
16880431METHODS OF NEUROPROTECTION INVOLVING MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR AGONISTSMay 2020August 2022Abandon2740NoNo
16874019CAVEOLIN-1 ANTIBODY FOR USE IN TREATING BRAIN INFLAMMATION AND INJURY AND IMPROVING FUNCTIONAL RECOVERYMay 2020July 2021Allow1420YesNo
16763906USE OF SRSF3 AGENTS FOR THE TREATMENT AND/OR PREVENTION OF NEUROLOGICAL CONDITIONS, CANCER, BACTERIAL INFECTIONS OR VIRAL INFECTIONSMay 2020August 2022Allow2711YesNo
16867324METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, AND OTHER DISORDERSMay 2020March 2022Abandon2310NoNo
16760487METHODS FOR TREATING TRAUMATIC BRAIN INJURYApril 2020February 2022Abandon2120NoNo
16857636TARGETING G3BP PROTEINS TO ACCELERATE NERVE REGENERATIONApril 2020November 2021Abandon1920NoNo
16852182PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING PARKINSON'S DISEASE COMPRISING STT AS AN ACTIVE INGREDIENTApril 2020August 2022Allow2810NoNo
16849515PROTEIN-INDUCED PLURIPOTENT CELL TECHNOLOGY AND USES THEREOFApril 2020February 2023Allow3410NoNo
16755461METHODS OF INDUCING COMPLEMENT ACTIVITYApril 2020August 2021Allow1610NoNo
16754954PRODUCTS AND METHODS ASSOCIATED WITH MULTIPLE SCLEROSIS AS A TRANSMISSIBLE PROTEIN MISFOLDING DISORDERApril 2020February 2023Abandon3411NoNo
16754576ANTI AQP3 MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOFApril 2020January 2022Allow2110YesNo
16842073METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED CONDITIONSApril 2020April 2021Allow1220NoNo
16753307ANTI-TRANSTHYRETIN ANTIBODIESApril 2020October 2021Allow1911YesNo
16838235ANTI-TAUC3 ANTIBODIES AND USES THEREOFApril 2020June 2021Allow1510NoNo
16820639COMPOSITION CONTAINING MIXED EXTRACT OF MULBERRY AND PORIA COCOS BARK FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERSMarch 2020November 2020Allow810NoNo
16820269COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASEMarch 2020August 2022Allow2910YesNo
16644695METHODS FOR DETECTION OF FOLATE RECEPTOR 1 IN A PATIENT SAMPLEMarch 2020June 2023Abandon4021NoNo
16810667TREATMENT OF DAMAGED NERVE WITH PTEN INHIBITORMarch 2020March 2022Abandon2420NoYes
16789626ANTIBODIES COMPRISING A COMMON LIGHT CHAIN AND USES THEREOFFebruary 2020October 2021Allow2010NoNo
16639050NOVEL NICOTINE-BINDING ANTIBODIESFebruary 2020May 2022Allow2700YesNo
16790066CLAUDIN 6 ANTIBODIES AND USES THEREOFFebruary 2020October 2021Allow2010NoNo
16788851ELECTROACTIVE POLYMERIC SCAFFOLDS AND METHOD FOR DELIVERING NERVE GROWTH FACTOR TO NERVE TISSUEFebruary 2020March 2022Allow2520NoYes
16637567TAU AGGREGATION PEPTIDE INHIBITORSFebruary 2020June 2022Allow2911YesNo
16782984AFFINITY-BASED METHODS FOR USING TRANSFERRIN RECEPTOR-BINDING PROTEINSFebruary 2020April 2023Abandon3820NoNo
16635796IMPROVED HUMAN �2-GLYCOPROTEIN I EXPRESSIONJanuary 2020January 2023Allow3620NoNo
16777290CHLOROGENIC ACID COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASEJanuary 2020January 2021Allow1110YesNo
16751886ASSAYS TO DETECT NEURODEGENERATIONJanuary 2020December 2020Allow1020NoNo
16633741METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONSJanuary 2020September 2022Abandon3131NoNo
16751120ANG (1-7) DERIVATIVE OLIGOPEPTIDES AND METHODS FOR USING AND PRODUCING THE SAMEJanuary 2020May 2021Allow1620NoNo
16751187STABLE COMPOSITIONS OF NEUROACTIVE PEPTIDESJanuary 2020October 2021Abandon2020NoNo
16749185Bicyclic Compounds and Methods for Their Use in Treating AutismJanuary 2020October 2021Allow2020YesNo
16746725HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAMEJanuary 2020September 2020Allow810NoNo
16744697BISPECIFIC HER2 ANTIBODIES AND METHODS OF USEJanuary 2020February 2023Allow3710YesNo
16631400TARGETING SYNAPTOGYRIN-3 IN TAUOPATHY TREATMENTJanuary 2020January 2022Allow2411YesNo
16631360SERUM ALBUMIN BINDING AGENTSJanuary 2020June 2021Allow1710NoNo
16630975ANTI-CD166 ANTIBODIES AND USES THEREOFJanuary 2020August 2021Allow1910YesNo
16736316FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTIONJanuary 2020August 2021Abandon2020NoNo
16731648REGULATING PROTEIN SPONTANEOUS RUPTURESDecember 2019November 2021Abandon2311NoNo
16726575NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASESDecember 2019September 2020Allow910NoNo
16626311PEDIATRIC OSTEOPOROSIS DRUG THAT DOES NOT CAUSE GROWTH DISORDERDecember 2019September 2021Allow2110NoNo
16625683NEW REAGENTS FOR OPTICAL MICROSCOPYDecember 2019July 2023Allow4320NoNo
16723143ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOFDecember 2019October 2020Allow1010NoNo
16715798ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDEDecember 2019April 2021Allow1620YesNo
16623254Compositions and Methods for Treating and Preventing Staphylococcus Aureus InfectionsDecember 2019October 2023Abandon4620NoYes
16712652HUMAN ALZHEIMER'S DISEASE AND TRAUMATIC BRAIN INJURY ASSOCIATED TAU VARIANTS AS BIOMARKERS AND METHODS OF USE THEREOFDecember 2019September 2022Allow3311NoNo
16618864NOVEL ANTI-HSA ANTIBODIESDecember 2019February 2022Allow2620YesNo
16616752Voltage-Gated Calcium Channel Auxilliary Subunit Alpha 2 Delta and Uses ThereofNovember 2019September 2023Abandon4511NoNo
16616262LIGANDS BINDING TO PRION PROTEIN FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIESNovember 2019July 2021Abandon2001NoNo
16686610BIOSENSOR FOR DIAGNOSING ALZHEIMER'S DISEASE USING RAYLEIGH SCATTERING AND COLORIMETRIC ASSAY OF GOLD NANOPARTICLE AND MULTI-DETECTION METHOD USING THE BIOSENSORNovember 2019December 2021Allow2521NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEIDNER, ADAM M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
38.2%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
33
Allowed After Appeal Filing
5
(15.2%)
Not Allowed After Appeal Filing
28
(84.8%)
Filing Benefit Percentile
19.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WEIDNER, ADAM M - Prosecution Strategy Guide

Executive Summary

Examiner WEIDNER, ADAM M works in Art Unit 1649 and has examined 606 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 23 months.

Allowance Patterns

Examiner WEIDNER, ADAM M's allowance rate of 62.5% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WEIDNER, ADAM M receive 1.77 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WEIDNER, ADAM M is 23 months. This places the examiner in the 84% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.7% benefit to allowance rate for applications examined by WEIDNER, ADAM M. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.7% of applications are subsequently allowed. This success rate is in the 48% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 48.4% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 69% percentile among all examiners. Of these withdrawals, 92.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 88.3% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.2% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.